Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 09:25 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Dose Titration Study to Assess the Effects of SAR407899 in Patients With MVA and/or Persistent Stable Angina Despite Angiographically Successful PCI
NCT03236311 · Sanofi · PHASE2 · terminated · last registry update 2022-03-24 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “(Recruitment was early terminated due to slow recruitment. Not linked to any safety concern.)” | – | Registry record, Sanofi |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against ROCK2 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2023-02-27Results posted on the registry: Aerie Pharmaceuticals, Netarsudil ophthalmic solution 0.02% + Ripasudil hydrochloride hydrate ophthalmic solution 0.4% (NCT04620135)
- 2023-02-06Results posted on the registry: Price Vision Group, Netarsudil + Placebo (NCT03971357)
- 2023-02-06Also stopped (terminated): Price Vision Group, Netarsudil + Placebo (NCT03971357)
- 2022-12-21Phase 3 first posted: Wills Eye, Netarsudil 0.02% Ophthalmic Solution [RHOPRESSA] + Glycerin 0.2%/Hypromellose 0.2%/Peg 1%/Soln,Oph,Ud (NCT05660447)
- 2022-09-08Results posted on the registry: Kadmon Corporation, LLC, Belumosudil (NCT02688647)
- 2022-09-06Phase 3 first posted: Kowa Research Institute, Inc., Ripasudil + Placebo (NCT05528172)
- 2022-09-01Results posted on the registry: Aerie Pharmaceuticals, Netarsudil Ophthalmic + Netarsudil Ophthalmic (NCT04498169)
- 2022-03-31Also stopped (withdrawn): University of California, San Diego, a drug against ROCK2 (NCT04064918)
- 2022-03-21Phase 3 first posted: Stanford University, Topical Ripasudil + Topical Placebo (NCT05289661)
- 2022-03-11Phase 3 first posted: Stanford University, Ripasudil + Placebo (NCT05275972)
- 2022-01-19Results posted on the registry: Aerie Pharmaceuticals, Netarsudil/Latanoprost 0.02%/0.005% + GANFORT® (NCT03284853)
- 2021-11-01Results posted on the registry: Kadmon Corporation, LLC, KD025 (NCT02317627)
- 2021-10-20Results posted on the registry: Kadmon Corporation, LLC, Belumosudil Tablet + Belumosudil Capsule (NCT02557139)
- 2021-09-24Results posted on the registry: Price Vision Group, Netarsudil Ophthalmic Solution + Placebo (NCT04051463)
- 2021-09-13Results posted on the registry: Kadmon Corporation, LLC, Belumosudil 200 mg tablet + [14C]-KD025 at a dose of 100 μg in a 5 mL solution IV microdose (NCT03907540)
- 2021-09-13Results posted on the registry: Kadmon Corporation, LLC, Belumosudil + Itraconazole (NCT03530995)
- 2021-09-13Results posted on the registry: Kadmon Corporation, LLC, Belumosudil (NCT02106195)
- 2021-09-13Results posted on the registry: Kadmon Corporation, LLC, Belumosudil + Placebo (NCT02852967)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision